Clinical Risk Factors for Retinopathy of Prematurity Reactivation after Intravitreal Antivascular Endothelial Growth Factor Injection - 18/09/24
Abstract |
Objective |
To assess the rate and risk factors for reactivation of retinopathy of prematurity (ROP) after intravitreal injection (IVI) of antivascular endothelial growth factor (VEGF) agents.
Study design |
Infants who received IVI therapy between 2017 and 2022 were enrolled and divided into 2 groups: those with and without ROP reactivation. Information on ROP variables and patient variables were analyzed using multivariable logistic regression.
Results |
A total of 114 infants with 223 eyes were enrolled in the study. The ROP reactivation rate was 11.4% of infants (9.9% of eyes). The mean duration of reactivation was 84 ± 45 days. Among the 223 eyes treated with IVI, reactivation rates were 6% for bevacizumab, 13.9% for aflibercept, and 22.2% for ranibizumab. A multivariable regression model showed that ranibizumab was an independent risk factor (OR 11.4, P = .008) for reactivation. Other risk factors included infants with periventricular leukomalacia (OR 13.8, P = .003), patent ductus arteriosus ligation (OR 10.7, P = .032), and infants who still required invasive mechanical ventilation on the day of IVI therapy (OR 7.0, P = .018).
Conclusions |
All anti-VEGF agents carry a risk of ROP reactivation, with the risk being greater with ranibizumab 0.25 mg than with bevacizumab 0.625 mg. Reactivation of ROP should be assessed vigilantly, especially in those infants with increased risks. Future research to determine the optimal anti-VEGF selection and dosage in high-risk infants is warranted.
Le texte complet de cet article est disponible en PDF.Keywords : retinopathy prematurity anti-VEGF
Abbreviations : IVI, PDA, PVL, PMA, ROP, RSS, VEGF
Plan
Vol 273
Article 113913- octobre 2024 Retour au numéro
Article précédent
- Research Training and Scholarly Activity during General Pediatric Residency in Canada
- Jimin Lee, Katharine V. Jensen, Asia L. van Buuren, Amarjot Padda, Zachary Dionisopoulos, Paul M. Ryan, Karen L. Forbes, Canadian Paediatric Inpatient Research Network Trainee Advisory Committee
- Reference Ranges for Arterial Oxygen Saturation, Heart Rate, and Cerebral Oxygen Saturation during Immediate Postnatal Transition in Neonates Born Extremely or Very Preterm
- Christina H. Wolfsberger, Bernhard Schwaberger, Berndt Urlesberger, Alexander Avian, Katharina Goeral, Marlene Hammerl, Tina Perme, Eugene M. Dempsey, Laila Springer, Gianluca Lista, Tomasz Szczapa, Hans Fuchs, Lukasz Karpinski, Jenny Bua, Brenda Law, Julia Buchmayer, Ursula Kiechl-Kohlendorfer, Lilijana Kornhauser-Cerar, Christoph E. Schwarz, Kerstin Gründler, Ilaria Stucchi, Katrin Klebermass-Schrehof, Georg M. Schmölzer, Gerhard Pichler, COSGOD III study group, Nariae Baik-Schneditz, Marlies Bruckner, Corinna Binder-Heschl, Christoph Schlatzer, Johann Martensen, Nina Höller, Evelyn Ziehenberger, Lukas Mileder, Angelika Berger, Sigrid Baumgartner, Agnes Grill, Michaela Mayr, Judith Rittenschober-Boehm, Michael Schneider, Christina Schreiner, Elke Griesmaier, Vera Neubauer, Peter Wöckinger, Anna Posod, Anja Marolt, Ana Dimnik, Vlasta Lubej Kurtovič, Garvey Aisling, Jurate Panaviene, David Healy, Nahla Ahmed, Ita Herlihy, Axel Franz, Francesca Castoldi, Francesco Cavigioli, Zuzanna Kozłowska, Marcin Minta, Zuzanna Owsiańska, Sonia Kahtan, Natalia Neumann- Klimasińska, Karolina Wróbel, Agata Kubiaczyk, Katarzyna Kosik, Katarzyna Olek, Michalina Bugiera, Julita Porwolik, Agnieszka Basiukajć, Elzbieta Czapla, Wojciech Łukaszuk, Katarzyna Gryczka, Dobrochna Naskręcka, Jan Mazela, Marta Szymankiewicz-Bręborowicz, Daniel Klotz, Jana Baumgartner, Jana Bembich, Laura Travan, Po-Yin Cheung
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?